Today, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials of semaglutide, an oral GLP-1 drug, in individuals with early-stage Alzheimer's disease, showing the trials did ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology ...

A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer’s disease and other neudegenerative conditions. The corresponding study was published in ACS ...

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, ...

From target identification and molecular design to patient stratification and clinical trial optimization, artificial intelligence (AI) is showing remarkable promise in accelerating drug discovery and ...

Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...

From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory ...

A Brisbane AI start-up company has partnered with tech giant Google in hopes of solving a dark secret plaguing the drug ...